NASDAQ:PHXM PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free PHXM Stock Alerts $3.10 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.10▼$3.1050-Day Range$2.50▼$3.7952-Week Range$2.50▼$13.00VolumeN/AAverage Volume2,472 shsMarket Capitalization$10.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get PHAXIAM Therapeutics alerts: Email Address Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About PHAXIAM Therapeutics Stock (NASDAQ:PHXM)PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Read More PHXM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHXM Stock News HeadlinesApril 15, 2024 | msn.comPhaxiam enrols first patient in endocarditis infection studyApril 15, 2024 | globenewswire.comPHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureusApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 5, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | globenewswire.comPHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)March 23, 2024 | seekingalpha.comONCT Oncternal Therapeutics, Inc.March 20, 2024 | globenewswire.comPHAXIAM Announces 2023 Full-Year Results and Provides Business UpdateMarch 11, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...March 11, 2024 | markets.businessinsider.comPhaxiam Therapeutics Says Delisting Of ADSs From Nasdaq EffectiveMarch 11, 2024 | globenewswire.comPHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 5, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024February 20, 2024 | globenewswire.comPHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 7, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024January 19, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 18, 2024 | finance.yahoo.comPHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 3, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023December 6, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023November 28, 2023 | lse.co.ukPhaxiam Therapeutics Share Price (PHXM.PA)November 15, 2023 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 14, 2023 | morningstar.comPHAXIAM Therapeutics SA ADR PHXMNovember 14, 2023 | finance.yahoo.comPHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 11, 2023 | morningstar.comPHAXIAM Therapeutics SA ADRNovember 7, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023October 29, 2023 | investing.comPhaxiam Therapeutics SA DRC (PHXM)October 24, 2023 | finance.yahoo.comPHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusOctober 23, 2023 | finanznachrichten.dePhaxiam Therapeutics S.A.: TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a "Buy" recommendationSee More Headlines Receive PHXM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PHAXIAM Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PHXM CUSIPN/A CIK1624422 Weberytech.com Phone33478744438Fax33-4-78-75-56-29Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.23 Current Ratio1.78 Quick RatioN/A Sales & Book Value Annual Sales$32.66 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$7.98 per share Price / Book0.39Miscellaneous Outstanding Shares3,412,000Free Float3,346,000Market Cap$10.58 million OptionableNo Data Beta2.35 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Eric Soyer Ph.D. (Age 58)Deputy CEO, Deputy GM, CFO & COO Comp: $415.06kDr. Jérôme Bailly Pharm.D. (Age 45)Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person Comp: $270.98kMr. Thibaut du Fayet (Age 56)Chief Executive Officer Ms. Céline Breda (Age 53)Chief Technology Officer Ms. Cindy FevreChief Scientific OfficerNaomi EichenbaumDirector Investor RelationsMs. Anne-Cécile Fumey (Age 48)Vice President of Human Resources Ms. Karine Charton Ph.D.Chief Business OfficerDr. Pascal Birman M.D.Chief Medical OfficerMs. Frederique VievilleChief Regulatory OfficerMore ExecutivesKey CompetitorsMonopar TherapeuticsNASDAQ:MNPRPurple BiotechNASDAQ:PPBTPlus TherapeuticsNASDAQ:PSTVVaccinexNASDAQ:VCNXPaxMedicaNASDAQ:PXMDView All Competitors PHXM Stock Analysis - Frequently Asked Questions How have PHXM shares performed in 2024? PHAXIAM Therapeutics' stock was trading at $4.44 at the beginning of 2024. Since then, PHXM stock has decreased by 30.2% and is now trading at $3.10. View the best growth stocks for 2024 here. When did PHAXIAM Therapeutics' stock split? PHAXIAM Therapeutics's stock reverse split on Wednesday, September 20th 2023. The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of PHAXIAM Therapeutics? Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHXM) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
